HomeCompareMDCP vs JNJ

MDCP vs JNJ: Dividend Comparison 2026

MDCP yields 0.04% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $288.00 in total portfolio value· pulled ahead in Year 7
10 years
MDCP
MDCP
● Live price
0.04%
Share price
$26.83
Annual div
$0.01
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$4.49
Full MDCP calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — MDCP vs JNJ

📍 JNJ pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDCPJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDCP + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDCP pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDCP
Annual income on $10K today (after 15% tax)
$3.81/yr
After 10yr DRIP, annual income (after tax)
$3.82/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $699.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDCP + JNJ for your $10,000?

MDCP: 50%JNJ: 50%
100% JNJ50/50100% MDCP
Portfolio after 10yr
$19.9K
Annual income
$416.14/yr
Blended yield
2.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MDCP
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDCP buys
0
JNJ buys
0
No recent congressional trades found for MDCP or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDCPJNJ
Forward yield0.04%3.36%
Annual dividend / share$0.01$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$19.7K$20.0K
Annual income after 10y$4.49$827.78
Total dividends collected$45.00$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MDCP vs JNJ ($10,000, DRIP)

YearMDCP PortfolioMDCP Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,704$4.48$10,676$355.77+$28.00MDCP
2$11,458$4.48$11,407$389.39+$51.00MDCP
3$12,265$4.48$12,198$426.53+$67.00MDCP
4$13,128$4.49$13,056$467.62+$72.00MDCP
5$14,051$4.49$13,987$513.12+$64.00MDCP
6$15,039$4.49$14,998$563.56+$41.00MDCP
7← crossover$16,097$4.49$16,098$619.52$1.00JNJ
8$17,228$4.49$17,295$681.69$67.00JNJ
9$18,438$4.49$18,599$750.82$161.00JNJ
10$19,734$4.49$20,022$827.78$288.00JNJ

MDCP vs JNJ: Complete Analysis 2026

MDCPStock

The adviser pursues the fund’s investment objective by investing, under normal circumstances, at least 80% of its assets in equity securities of mid-cap companies. The adviser considers “mid-cap companies” to be companies with market capitalizations that, at the time of initial purchase, are within the capitalization range of companies comprising the Russell Mid Cap Index. Generally, the adviser expects the fund will hold approximately 30 securities. The equity securities in which the fund invests are primarily common stocks. In addition, the fund may invest in foreign securities, including ADRs and GDRs.

Full MDCP Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this MDCP vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDCP vs SCHDMDCP vs JEPIMDCP vs OMDCP vs KOMDCP vs MAINMDCP vs ABBVMDCP vs MRKMDCP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.